Eyepoint, Inc. · NASDAQ:EYPT
Eyepoint — EyePoint Pharmaceuticals — OIS (Ophthalmology Innovation Summit) – Spotlight on Drug Delivery, July 2023
19 slides from Eyepoint's conference presentation, Jul 27, 2023
Slide 1: Spotlight on Drug Delivery
Nancy Lurker, Executive Vice Chair, Board of Directors | OIS | July 27, 2023 Spotlight on Drug Delivery Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activit
Slide 3: Committed to developing therapeutics to improve the lives of patients with serious eye disorders
Committed to developing therapeutics to improve the lives of patients with serious eye disorders COMPANY OVERVIEW Pipeline represents multi billion-dollar opportunity EYP-1901 –bioerodible intravitreal (IVT) insert of patented vorolanib tyrosine kinase inhibitor (TKI) for retinal disease Topline Pha
Slide 4: EYP-1901 Phase 2 DAVIO Clinical Trial Results
EYP-1901 PHASE 1 DAVIO CLINICAL TRIAL RESULTS
Slide 5: EYP-1901 Phase 2 DAVIO Clinical Trial Met All Objectives
EYP-1901 Phase 1 DAVIO Clinical Trial Met All Objectives FAVORABLE SAFETY PROFILE Stabilization of mean BCVA and OCT throughout 6 months was achieved 53% up to 6-months with no anti-VEGF supplemental injection 75% reduction in treatment burden at 6-months No ocular SAEs reported No drug-related syst
Slide 6: BCVA and CST Stable After Single Treatment Of EYP-1901 In The DAVIO Clinical Trial
BCVA and CST Stable At 6 And 12 Months After Single Treatment Of EYP-1901 In The DAVIO Clinical Trial AVERAGE CHANGE IN BCVA FROM SCREENING VISIT AVERAGE CHANGE IN CST FROM SCREENING VISIT ALL (N=17) MONTHS ALL (N=17) MONTHS BCVA: best corrected visual acuity OCT: optical coherence tomography; CST:
Slide 7: Wet AMD Phase 2 Clinical Trial - DAVIO 2 EYP-1901
WET AMD PHASE 2 CLINICAL TRIAL - DAVIO 2 EYP-1901
Slide 8: EYP-1901 Phase 2 DAVIO 2 Clinical Trial Is Randomized, Double-Masked, Aflibercept Controlled
EYP-1901 Phase 2 DAVIO 2 Clinical Trial Is Randomized, Double-Masked, Aflibercept Controlled With A Single EYP-1901 Treatment At Two Doses -D14 to -D7 D1 W4 W8 W12 W16 W24 W32 W36 to W56 W20 W28 EYP-1901 2mg low dose EYP-1901 3mg high dose Aflibercept q8W RANDOMIZATION REQUIRED AFLIBERCEPT INJECTION
Slide 9: Ph 2 DAVIO and Ph 2 DAVIO 2 Study Demographics
Ph 1 DAVIO and Ph 2 DAVIO 2 Study Demographics Phase 1 DAVIO Baseline Characteristics (N = 17) Mean age, y (range) 77.4 (67-94) Female, % 76% Mean BCVA, ETDRS letters (range) 69 (38-85) Mean CST, μm (range) 299 (204-441) AMD, age-related macular degeneration; BCVA, best-corrected visual acuity; CST,
Slide 10: Masked Safety Summary As Of July 1, 2023 Data-Cut Off
Masked Safety Summary As Of July 1, 2023 Data-Cut Off Key findings: No drug-related ocular SAEs No drug-related systemic SAEs 2 ocular SAEs: Retinal detachment in a study eye detected at week 1 (one week post initial aflibercept injection, prior to EYP-1901 injection) Retinal hemorrhage in a non-stu
Slide 11: Phase 2 DAVIO Clinical Trial Subgroup Analysis – Nine Subjects With No Excess Fluid At Screening
PHASE 1 DAVIO CLINICAL TRIAL SUBGROUP ANALYSIS – NINE SUBJECTS WITH NO EXCESS FLUID AT SCREENING EYP-1901
Slide 12: Subgroup Analysis: 89% Reduction In Treatment Burden Among Mid/High Dose Subjects
Subgroup Analysis: 89% Reduction In Treatment Burden At 12 Months Among Mid/High Dose Subjects With No Excess Fluid At Screening (n=6) SOC, standard of care; VEGF, vascular endothelial growth factor. DAVIO Final 12-Months Data SOC (Anti-VEGF) + EYP-1901 SOC Anti-VEGF Injections Before and After Trea
Slide 13: Vorolanib: A Potent Pan-VEGF Receptor Inhibitor
Vorolanib: A Potent Pan-VEGF Receptor Inhibitor Vorolanib inhibits pathways with key roles in angiogenesis: Potent and selective pan–VEGF receptor inhibitor Acts intracellularly and inhibits proangiogenic signaling DAVIO Final 12-Months Data ANG, angiopoietin; PDGF(R), platelet-derived growth factor
Slide 14: Vorolanib Demonstrated The Ability To Provide Retinal Neuroprotection In Validated Mouse Model
Vorolanib Demonstrated The Ability To Provide Retinal Neuroprotection In Validated Mouse Model 34% reduction in loss of contrast vision vs. control Mean Change in Contrast Vision at Day 16 from Baseline in Animals Treated with Vorolanib vs Vehicle Control Retinal thickness measured by vertical and h
Slide 15: Non-Proliferative Diabetic Retinopathy - Phase 2 Clinical Trial (PAVIA) EYP-1901
NON-PROLIFERATIVE DIABETIC RETINOPATHY - PHASE 2 CLINICAL TRIAL (PAVIA) EYP-1901
Slide 16: EYP-1901 Phase 2 PAVIA Clinical Trial Is Randomized Double-Masked, Single Injection With Sham Control
EYP-1901 Phase 2 PAVIA Clinical Trial Is Randomized Double-Masked, Single Injection With Sham Control As A 9-Month Treatment In NPDR EYP-1901 DOSING VISIT SCHEDULED SHAM INJECTION -D21 to –D5 D1 W4 W12 W24 W36 W48 EYP-1901 2mg low dose (n=35) EYP-1901 3mg high dose (n=35) Control Sham (n=35) RANDOMI
Slide 17: Pipeline Represents Multibillion Dollar Opportunity
Pipeline Represents Multibillion Dollar Opportunity Program Indication Discovery Pre-Clin Phase 1 Phase 2 Phase 3 Next Milestone EYP-1901 – (vorolanib in Durasert E™) wet AMD NPDR DME ack Complement programs Dry AMD GA Topline data in Q2 2024 Topline data in December 2023 single dose 6-month mainten
Slide 18: Continued Execution And Well Funded Through Key EYP-1901 Milestones
Continued Execution And Well Funded Through Key EYP-1901 Milestones EYP-1901 Corporate ✓ DAVIO 1 trial complete 2Q 2022 ✓ DAVIO 2 trial initiated 3Q 2022 ✓ PAVIA trial initiated 3Q 2022 ✓ DAVIO 2 enrollment complete 1Q 2023 ✓ PAVIA enrollment complete 2Q 2023 DAVIO 2 topline data December 2023 DME T
Slide 19: Thank you!
Spotlight on Drug Delivery Nancy Lurker | OIS | July 2023 Thank you!